Royalty Report: Drugs, Cancer, Pharmaceuticals – Collection: 27843

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 27843

License Grant
University hereby grants an exclusive worldwide license, in the Field of Use under the Patent Rights and to utilize the Know-how and Improvements, throughout the License Period, to (a) make, have made, use, lease, offer for sale, sell and import any Licensed Products and to practice and have practiced any Licensed Processes; and (b) sublicense to third parties, in accordance with Article 4 below, the rights granted under subparagraph (a) of this Paragraph 3.01 (together with (a), the “Licensed Patent Rights”).
License Property
University owns certain inventions, conceived at University and assigned by the inventors to OHSU as described in Appendix A, wherein such inventions, as well as any related confidential matter, pertain to thiol-based chemoprotectant compounds and chemosensitizers their use in oncology and other disorders, pharmaceutical compositions and other thiol-based technologies (the “Technology”).

STS is currently marketed for use in humans as part of a treatment for cyanide poisoning.  The Licensee has Licensed intellectual property rights for the use of STS as a chemoprotectant, and are developing STS as a protectant against the hearing loss often caused by platinum-based anti-cancer agents, in both children and adults.  We have received Orphan Drug Designation in the United States for the use of STS in the prevention of platinum-induced ototoxicity in pediatric patients.

Licensed Patent or Patent Applications

Item
  
Patent
  
Application
  
Serial
  
Country
  
Title
  
Inventors
  
Filing
  
Issue Date
  
Current
  
Uni Ref

#

No

No.

No.

Date

Status

No.

1
  
5124146
  
644331
  
N/A
  
US
  
Differential delivery of therapeutic agents across the blood brain barrier
  
Neuwelt
  
33260
  
33778
  
Published
  
OHSU #120

Int’l

2
  
N/A
  
N/A
  
PCT/US01/40624
  
US
  
Administration of a thiol based chemoprotectant compount
  
Neuwelt
  
36642
  
N/A
  
Nationalization due 26 Oct 2002 Draft of claims written to be filed Oct 16
  
OHSU

WO 01/80832

Int’l

# 493

60/199,936

60/229/870

2 a)
  
N/A
  
N/A
  
60/229,870
  
Provisional
  
Chemoprotectant compounds for protection against organ damage
  
Neuwelt
  
36768
  
N/A
  
Pending
  
OHSU

Muldoon

#493 continued

2 b)
  
N/A
  
N/A
  
60/199,936
  
Provisional
  
Localised administration of a thiol based chemoprotectant compount against myelosuppression
  
Newwelt
  
36642
  
N/A
  
Pending
  
OHSU

Muldoon

#493

Pagel

continued

3
  
N/A
  
N/A
  
PCT/USO1/27296
  
US
  
Chemoprotectant for gastric toxicity
  
Neuwelt
  
36768
  
N/A
  
Nationalization due Feb 28, 2003
  
OHSU

60/229,869

Int’l

Muldoon

# 512

3 a)
  
N/A
  
N/A
  
60/229,869
  
Provisional
  
Chemoprotectant for gastric toxicity
  
Neuwelt
  
36768
  
N/A
  
Pending
  
OHSU

Muldoon

# 512

4
  
N/A
  
N/A
  
In progress
  
Provisional
  
Prevention of mucositis and related diseases along the GI tract
  
Neuwelt
  
In progress
  
N/A
  
In progress
  
493-B

5
  
N/A
  
N/A
  
Pending
  
Provisional
  
Administration of NAC to diminish infarction volume
  
Neuwelt
  
37519
  
N/A
  
Pending
  
493-A

6
  
4800042
  
122027
  
07/122,027
  
US
  
Method for the delivery of genetic material across the blood brain barrier
  
Neuwelt
  
32099
  
32763
  
Published
  
OHSU

Int’l

# 121

7
  
5059415
  
314940
  
07/314,940
  
US
  
Method for diagnostically imaging lesions in the brain inside a blood brain barrier
  
Newwelt
  
32560
  
33533
  
Published
  
OHSU

Int’l

# 131

The present invention generally relates to a method for delivering therapeutic agents into the brain, and more specifically to such a method in which the therapeutic agents are delivered across the blood brain barrier.

5,124,146 A method for the delivery of therapeutic agents across the blood brain barrier is disclosed which utilizes drug neutralization technology, and the selective permeability o This invention was made with support by the Preuss Foundation and with Government support by the Veterans Administration and under Grant No. 31770 awarded by the National Institutes of Health. The Government has certain rights in this invention.

IPSCIO Record ID: 7467

License Grant
The exclusive License grants rights to intellectual property directed to Sodium Thiosulfate (STS) and its use for chemoprotection, including the prevention of ototoxicity induced by platinum chemotherapy, in humans. Preclinical and clinical studies have indicated that STS can effectively reduce the incidence of hearing loss caused by platinum-based anti-cancer agents.

IPSCIO Record ID: 5499

License Grant
Licensor was formed by licensee to aid in acquiring development funds.  License grants an exclusive interim license to manufacture and market RMPs and Cereport for human pharmaceutical use in the United States and Canada. Designation of European rights are not explained.

The transaction assigned rights to a family of molecules designated as Receptor-Mediated Permeabilizers(TM) (RMPs(TM)), including Cereport.

License Property
Cereport improves the passage into the brain of certain pharmaceutical compounds by increasing transiently the permeability of the blood brain barrier.  It is being tested in conjunction with the chemotherapy agent carboplatin for the treatment of brain tumors.  Patent #5,112,596 and 5,268,164.
Field of Use
The rights granted are for human pharmaceutical use.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.